NYSE · WAT
Healthcare · Medical - Diagnostics & Research
$401.64▼ 0.78% ($3.17)at close
Pre-market$403.01▲ 0.34%·7:27 AM ET
To support a price of $401.64, this model requires revenue to grow by 41.21%/yr over the next 10 years, compounded annually.
Historical revenue grew by 3.24%/yr over the past 4 years. The required annual growth rate is 37.97 percentage points higher.
Selected forecast · Base scenario
19.42%/yr · actual 10-year annualized revenue growth
Year 1 growth: 38.86%
Market-implied · Base operating assumptions + edited margins
41.21%/yr · flat 10-year annualized revenue growth
Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.
Price used
$401.64
Estimated value / share
$66.79
Base scenario
This estimate is 83.37% below the price used.
Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
Year 1 growth 38.86% · Ending margin 7.96% · Discount rate 10.65%
Assumption scenarios, not statistical confidence intervals.
Estimated from future revenue, operating margins, and the investment needed to support them.
FCFF is positive, but the series is too unstable to anchor a direct cash-flow CAGR and the business still fails the steady-state comparability checks. Use a revenue-and-margin transition model instead of normalizing and compounding current FCFF.
Is FCFF positive and has it been for 3+ consecutive years? 28 consecutive positive FCFF years are available.
Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 33.0%.
Do you have 5+ years of positive FCFF history? 28 consecutive positive FCFF years are available.
Is the business model structurally similar to what it should be in 10 years? Revenue is still growing 113.3%, above the 15.0% maturity threshold, so a steady-state FCFF model would lean too heavily on a business still scaling.
WAT
Price vs Fundamentals
The stock rose 37.06% over the last year. Revenue grew 52.47% over the trailing twelve months. Operating margin moved from 27.69% to 7.96%. Free cash flow declined 35.67% over the trailing twelve months.
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
Operating margin currently stands at 7.96%. A decisive move in revenue — currently up 52.47% — would be the clearest signal to resolve the ambiguity.
Performance
Company profile
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe.
Market multiples
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
19
Buy
16
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 3, 2026
Q4 FY26 · EPS est $4.01 · Revenue est $1.75B
View
Market cap
$30.04B
P/E
237.41
Volume
572.37K
Shares outstanding
74.79M